News
PHVS
32.99
-0.24%
-0.08
Insider Move at Pharvaris Sparks Fresh Investor Attention
TipRanks · 1h ago
Top Pharvaris Executive Makes Attention-Grabbing Move With Company Stock
TipRanks · 1d ago
Trade Alert: Independent & Non-Executive Vice Chairman Of Pharvaris Hans J. G. C. Schikan Has Sold Stock
Simply Wall St · 1d ago
Pharvaris (PHVS) Gets a Buy from H.C. Wainwright
TipRanks · 3d ago
Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 3d ago
Weekly Report: what happened at PHVS last week (0914-0918)?
Weekly Report · 3d ago
Top Pharvaris Executive Cashes In on Major Insider Stock Sale
TipRanks · 09/18 02:05
How Investors May Respond To Pharvaris (PHVS) Phase 3 HAE Trial Success
Simply Wall St · 09/17 23:26
Is Pharvaris (PHVS) Too Expensive After Its Phase 3 Results?
Simply Wall St · 09/16 11:24
Pharvaris N.V. Consensus Price Target Raised 20.08% to $59.77
NASDAQ · 09/15 02:47
Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 09/14 11:55
Weekly Report: what happened at PHVS last week (0907-0911)?
Weekly Report · 09/14 09:03
Pharvaris (PHVS) Could Be Deeply Undervalued As Phase 3 HAE Data Strengthens Its Case
Simply Wall St · 09/13 00:22
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
NASDAQ · 09/11 16:06
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Seeking Alpha · 09/11 14:16
Pharvaris Is Maintained at Buy by Guggenheim
Dow Jones · 09/10 14:27
Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44
Benzinga · 09/10 14:17
Phase 3 Trial Win Could Be A Game Changer For Pharvaris Stock (PHVS)
Simply Wall St · 09/10 12:32
Pharvaris price target raised to $44 from $40 at Guggenheim
TipRanks · 09/10 11:35
Analysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (XERS) and Pharvaris (PHVS)
TipRanks · 09/10 11:10
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.